Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Duragesic · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Fentanyl patch 25 ug/hr Sandoz |
| 2 | ACTIVE_COMPARATOR | Duragesic Patch 25 ug/hr |
| Name | Type | Description |
|---|---|---|
| Fentanyl patch 25 ug/nr Sandoz | DRUG | - |
| Duragesic | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal findings on physical exam, medical history or clinical laboratory tests on screening. Exclusion Criteria: * Negative test for HIV and hepatitis B and C * No history of drug or alcohol treatment * No allergies to opiates
Duragesic is used for pain. It is a small molecule drug being developed by Novartis AG. The drug is currently in Phase 1 clinical development, meaning it is investigational and has not yet been approved for use. One clinical trial has been completed for this indication.
Duragesic is developed by Novartis AG, which trades under the ticker symbol NVS. The drug is a small molecule being studied for the treatment of pain. It is currently in Phase 1 clinical development, with one completed trial.
Duragesic is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied for pain. One Phase 1 trial has been completed, involving 40 participants. The drug is not currently in active clinical trials.
Duragesic has one completed clinical trial, NCT00857753, titled "Relative Bioavailability of a Fentanyl Patch." This Phase 1 study enrolled 40 participants and was active-controlled, though not double-blinded. The trial involved healthy volunteers aged 18 years and older.
Duragesic is a fentanyl patch, as indicated by the clinical trial title "Relative Bioavailability of a Fentanyl Patch." The drug is a small molecule developed by Novartis AG for pain. It is currently in Phase 1 development, with one completed trial.